Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.720
+0.080 (3.03%)
Jun 4, 2025, 2:04 PM - Market open
Spero Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Spero Therapeutics stock have an average target of 5.00, which predicts a 83.82% increase from the current stock price of 2.72.
Price Target: $5.00 (+83.82%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 30, 2025.
Analyst Ratings
The average analyst rating for Spero Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +83.82% | Jan 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades $5 | Buy → Hold | Downgrades | $5 | +83.82% | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +83.82% | Dec 2, 2024 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Nov 15, 2024 |
Financial Forecast
Revenue This Year
6.02M
from 47.98M
Decreased by -87.46%
Revenue Next Year
1.33M
from 6.02M
Decreased by -77.97%
EPS This Year
-1.27
from -1.27
EPS Next Year
-0.13
from -1.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.2M | 1.4M | 34.1M | ||
| Avg | 6.0M | 1.3M | 33.2M | ||
| Low | 5.8M | 1.3M | 31.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -87.1% | -77.3% | 2,473.5% | ||
| Avg | -87.5% | -78.0% | 2,400.0% | ||
| Low | -87.9% | -78.8% | 2,302.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.18 | 1.81 | -1.87 |
| Avg | -1.27 | -0.13 | -1.82 |
| Low | -2.27 | -1.94 | -1.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.